A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy

NCT ID: NCT01218854

Last Updated: 2025-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-20

Study Completion Date

2016-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Currently, standard procedures for biopsies that are guided by computed tomography (CT) imaging involve CT scans and a computer program to plan and illustrate where the physician will place the needle to obtain the required cells or tissue. Inserting the biopsy needle at the planned angle is not an easy task, because the appropriate angle of insertion must be estimated based on prior experience. Researchers are studying experimental techniques that might provide better guidance about the right angle to insert the biopsy needle and thereby improve the collection of the appropriate biopsy cells or tissue.

Objectives:

\- To evaluate the effectiveness of two biopsy needle guidance methods in CT-guided tissue biopsy.

Eligibility:

\- Individuals at least 18 years of age who are scheduled to have CT-guided tissue biopsy.

Design:

* Participants will have a tissue biopsy guided by CT scans and either a laser system or a plastic block to illustrate the appropriate angle of insertion. The skin will be numbed with anesthetic to minimize discomfort during the procedure.
* Before inserting the biopsy needle, the study physician will hold the needle in place so that a Food and Drug Administration-approved medical GPS (electromagnetic tracking) system can measure the needle angle as it enters the tissue.
* After the needle angle data has been collected, researchers will proceed with the actual biopsy procedure as it would normally occur, using standard methods.
* No additional treatment will be provided as part of this protocol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

* Currently, standard/conventional CT-guided biopsies proceed as follows the physician:

1. obtains a pre-procedural CT scan,
2. plans the needle s angle based on this CT scan,
3. selects the angle at which the needle should be inserted based on the pre-procedural CT scan,
4. inserts the needle while aiming to replicate that planned needle angle by using only their visual-spatial abilities, and
5. re-images the patient to confirm needle location followed by needle

repositioning, if needed.
* Improving upon these standard methods of needle placement could have

widespread benefits (e.g. improved diagnostic tissue sampling, decreased

needle repositionings, etc.) We will be studying three needle angle selection systems. The laser-assisted needle angle selection system or LNASS, is a custom fabricated device that uses a Class II pointer similar to ones used for pointing at slides during lectures.

Objectives:

* To compare the angle difference between L-NASS (Method A) and the standard method (clinician intuition/conventional method)
* To compare the angle difference between B-NASS (Method B) and the standard method (clinician intuition)
* To compare the angle difference between the mobile device-NASS or MD-NASS (C) and the standard method (clinician intuition/conventional method)

Eligibility:

* Ages Eligible for Study: 18 Years and older
* Genders Eligible for Study: Both
* Inclusion:

* Must be undergoing a scheduled CT-guided biopsy.
* Must have ability to follow breathing instructions like holding breath (if procedure is to be performed without general anesthesia).
* Exclusion:
* No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation.
* Any known allergy to plastics or polymers (since the Ultem polymer could theoretically induce a rash in these patients, even though it is hypoallergenic).
* Pacemakers or automatic implantable cardiac defibrillators.
* Gross body weight above the CT table limit (450 pounds).

Design:

* Primary outcome measure for the first arm is:

--The difference between planned and achieved needle angle of a laser-assisted needle angle selection system with the standard method (clinician s intuition or conventional method) of CT-guided biopsy.
* Primary outcome measure for the second arm is:

--The difference between planned and achieved needle angle of a block with pre-drilled needle angles with the standard method (clinician s intuition or conventional method) of CT-guided biopsy
* Primary outcome for the third arm is:

--The difference between planned and achieved needle angle of a mobile device-assisted needle angle selection system with the standard method (clinician's intuition or conventional method) of CT-guided biopsy.
* The tool for measuring the needle angles will be an FDA-approved electromagnetic tracking system, which tracks needle movement and position.
* These comparisons will be done as a bystander study.
* Needle guidance system will only be used initially to select the angle during a superficial, shallow needle insertion at the skin surface (less than 1 cm deep).
* At no time will the needle enter tissue that it wouldn t have otherwise entered as none of the system will be used to perform the biopsies at this time.
* The key portions of the procedure will not be altered in any substantive way.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms Liver Neoplasms Kidney Neoplasms Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B-NASS

Block assisted needle angle selection system

Group Type EXPERIMENTAL

Needle angle measurement

Intervention Type DEVICE

The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

L-NASS

laser assisted needle angle selection system

Group Type EXPERIMENTAL

Needle angle measurement

Intervention Type DEVICE

The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

MD-NASS

mobile-device assisted needle angle selection system

Group Type EXPERIMENTAL

Needle angle measurement

Intervention Type DEVICE

The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Needle angle measurement

The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must fulfill all of the following criteria to be eligible for study admission:

* All patients must be undergoing a CT-guided biopsy.
* Age greater than 18 years.
* No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation.
* The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. If in question, an ethics consult will be obtained.
* Ability to follow breathing instructions like holding breath (if procedure is to be performed without general anesthesia).
* Patients must be actively enrolled on an NIH protocol and be scheduled for a CT-guided biopsy.

Exclusion Criteria

* Patients with an altered mental status that precludes understanding or consenting for the biopsy procedure will be excluded from this study.
* Patients unlikely to be able to hold reasonably still on a procedure table for the length of the procedure.
* Patients with any known allergy to plastics or polymers (since the Ultem -polymer could theoretically induce a rash in these patients, even though it is hypoallergenic).
* Inability to follow breathing instructions, if without general anesthesia.
* Patients with pacemakers or automatic implantable cardiac defibrillators.
* Gross body weight above the CT table limit (450 pounds).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health Clinical Center (CC)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bradford J Wood, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Institutes of Health Clinical Center (CC)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Miaux Y, Guermazi A, Gossot D, Bourrier P, Angoulvant D, Khairoune A, Turki C, Bouche E. Laser guidance system for CT-guided procedures. Radiology. 1995 Jan;194(1):282-4. doi: 10.1148/radiology.194.1.7997570.

Reference Type BACKGROUND
PMID: 7997570 (View on PubMed)

Pereles FS, Baker M, Baldwin R, Krupinski E, Unger EC. Accuracy of CT biopsy: laser guidance versus conventional freehand techniques. Acad Radiol. 1998 Nov;5(11):766-70. doi: 10.1016/s1076-6332(98)80260-2.

Reference Type BACKGROUND
PMID: 9809074 (View on PubMed)

Jacobi V, Thalhammer A, Kirchner J. Value of a laser guidance system for CT interventions: a phantom study. Eur Radiol. 1999;9(1):137-40. doi: 10.1007/s003300050644.

Reference Type BACKGROUND
PMID: 9933397 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-CC-0217

Identifier Type: -

Identifier Source: secondary_id

100217

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.